BioSpace News Archive

Aquestive Therapeutics, Inc. announced that it has submitted an Investigational New Drug application to the U.S. FDA for pharmacokinetic clinical trials of its drug candidate AQST-108, a “first of its kind” oral sublingual film formulation delivering systemic epinephrine that is in development for the treatment of anaphylaxis using Aquestive’s proprietary PharmFilm® technologies.

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, announced that due to faster-than-expected enrollment, the Company anticipates topline Phase 3 RELIEF results in the fourth quarter of 2020, rather than the first quarter of 2021 as previously guided.

Aprea Therapeutics Inc., a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein, announced the appointments of Fouad Namouni, M.D. and Richard Peters, M.D., Ph.D. to its Board of Directors.

Zimmer Biomet Holdings, Inc. announced its second quarter earnings conference call will be webcast on Tuesday, August 4, 2020, at 8:30 a.m. ET.

The global proteinase K market is set to grow at a sturdy rate over the forecast period of 2019 to 2029 owing to factors such as growing cases of contamination that require demand for purification.

The demand within the global patient lifting devices market is expected to rise in the years to follow.

China Biologic Products Holdings, Inc. declared that the Company disagrees with the notice delivered by Xinjiang Deyuan Bioengineering Co., Ltd. to China Biologic, which attempts to terminate the cooperation between China Biologic and Xinjiang Deyuan, and urges Xinjiang Deyuan to cure its breaches and continue to perform its obligations under its cooperation agreement with China Biologic.

ULTOMIRIS is the first and only long-acting C5 inhibitor for aHUS, administered every other month, reducing the treatment burden for adults and children

Merz Pharmaceuticals GmbH and Teijin Pharma Limited jointly announced that Teijin Pharma has been granted approval by Japan’s Ministry of Health, Labor and Welfare to market Xeomin® for intramuscular injection in 50, 100 or 200 units for the treatment of upper limb spasticity.

The acquisition supports the expansion of the Brainlab business, accelerating technology adoption and broadening the company’s reach